Department of Oncology, University Hospital of Vaudois (CHUV), Lausanne, Switzerland.
Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12.
The recent approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC) in the US and other countries has provoked intense interest in ALK rearrangements as oncogenic drivers, and promises to revolutionise the way in which NSCLC is diagnosed and treated. Here, we review clinical data to date for the use of crizotinib to treat patients with advanced, ALK-positive NSCLC and consider issues surrounding the detection of ALK-positivity including the use of fluorescence in situ hybridisation and the other potential techniques available, and their suitability for ALK screening. We also discuss the emergence of resistance to crizotinib therapy and the range of other ALK inhibitors currently in development.
克唑替尼最近在美国和其他国家获批用于治疗间变性淋巴瘤激酶（ALK）重排的晚期非小细胞肺癌（NSCLC），这引发了人们对 ALK 重排作为致癌驱动因素的浓厚兴趣，并有望彻底改变 NSCLC 的诊断和治疗方式。在此，我们回顾了迄今为止使用克唑替尼治疗晚期 ALK 阳性 NSCLC 患者的临床数据，并探讨了检测 ALK 阳性的相关问题，包括荧光原位杂交的应用以及其他可能的检测技术，及其在 ALK 筛查中的适用性。我们还讨论了对克唑替尼治疗产生耐药的问题，以及目前正在开发的其他 ALK 抑制剂。
